Quanterix Corporation (QTRX)
Market Cap | 650.59M |
Revenue (ttm) | 125.98M |
Net Income (ttm) | -36.30M |
Shares Out | 38.27M |
EPS (ttm) | -0.96 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 472,101 |
Open | 15.90 |
Previous Close | 15.62 |
Day's Range | 15.35 - 17.03 |
52-Week Range | 14.26 - 29.70 |
Beta | 1.50 |
Analysts | Strong Buy |
Price Target | 30.33 (+78.41%) |
Earnings Date | Aug 5, 2024 |
About QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of ... [Read more]
Financial Performance
In 2023, Quanterix's revenue was $122.37 million, an increase of 15.96% compared to the previous year's $105.52 million. Losses were -$32.33 million, -66.56% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for QTRX stock is "Strong Buy." The 12-month stock price forecast is $30.33, which is an increase of 78.41% from the latest price.
News
Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...
Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...
Quanterix Releases Financial Results for the First Quarter of 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fi...
Quanterix To Report First Quarter 2024 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership...
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phosph...
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fo...
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, ...
Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer's Disease
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaboratio...
Quanterix to Present at Cowen's 44th Annual Health Care Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference ca...
Quanterix to Present at 42nd Annual J.P. Morgan Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Exe...
Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Exe...
Quanterix Releases Operating Results for Third Quarter 2023
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation today announced financial results for the three months ended September 30, 2023.
Quanterix Releases Operating Results for Third Quarter 202
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation today announced financial results for the three months ended September 30, 2023.
Quanterix to Report Third Quarter 2023 Financial Results on November 7, 2023
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financia...
Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high a...
Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced the signing of a licen...
Quanterix CEO to Speak at Goldman Sachs Alzheimer's Disease Day
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...
Quanterix to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...
William P. Donnelly Appointed to Quanterix's Board of Directors
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced...
Quanterix Appoints Vandana Sriram as Chief Financial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced...
Quanterix Releases Operating Results for Second Quarter 2023
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the th...
Quanterix to Present at Canaccord Genuity 43rd Annual Growth Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...
Quanterix's Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced...